To improve the standardisation, reproducibility and comparability of cardiolipin tests and results, European Forum on Antiphospholipid Antibodies recommended recently to include the monoclonal antibodies HCAL and EY2C9 as external controls in cardiolipin and ß2-GPI antibody testing.
AESKU.Diagnostics, the manufacturer of the largest panel of anti-phospholipid antibody ELISA tests worldwide, has now implemented those so-called Sapporo standards in the production and quality control procedure of the AESKULISA® cardiolipin and ß2-GPI tests.
Hence the AESKULISA® cardiolipin tests are not only standardised according to the Harris sera for the IgG, IgM, and IgA isotypes as well as the UK NEQAS standard preparation 97/656 for IgG but from now on also according to the Sapporo standards for both IgG and IgM. This results in extraordinary stable and reproducible ELISA tests for the detection of anti-cardiolipin antibodies.
For both the AESKULISA® cardiolipin as well as ß2-GPI, tests for the separate detection of IgG, IgM and IgA antibodies are available but also Check tests using a mixed conjugate for the combined detection of all three isotypes allowing a rapid and easy screening for anti-phospholipid antibodies.
One colour code, one sample dilution, one cut off, one standard curve, one substrate, one buffer system for all products - the AESKULISA® anti-phospholipid tests share of course all benefits of the whole product line.